Why these 4 ASX shares have started the week higher

It has been another disappointing day of trade for the benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). In afternoon trade the index is down slightly to 6,003 points.

Four shares which haven’t let that hold them back are listed below. Here’s why they have started the week higher:

The Auscann Group Holdings Ltd (ASX: AC8) share price has climbed 2.5% to $1.64 after announcing an agreement with Australian Pharmaceutical Industries Ltd (ASX: API). The two companies aim to form a wholesale agreement for the distribution of AusCann’s cannabinoid medicines throughout Australia. I think this is a big step forward and could put AusCann in a strong position as a first-mover in the industry.

The Bellamy’s Australia Ltd (ASX: BAL) share price is over 3% higher at $14.97 despite there being no news out of the infant formula company. However, a positive trading update and guidance increase last week appears to have investors fighting to get hold of its shares. I think it has been a remarkable turnaround for Bellamy’s and there could still be plenty of upside for its shares in the next 12 months.

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is up 5% to 10.5 cents after its 51%-owned MGC Derma business signed a strategic distribution agreement with world-renowned online beauty store, Cult Beauty. The deal will see 15 of MGC Derma’s cannabidiol cosmetic products sold on the Cult Beauty site after launching on February 1.

The Topbetta Holdings Ltd (ASX: TBH) share price has jumped 5% to 41 cents following the release of its quarterly update. According to the release, the company recorded quarterly wagering and tournament revenue of $82.9 million in the December quarter. This was a 52% increase on the September quarter and well ahead of its guidance of $75 million.

Finally, here are three top growth shares to buy today if you missed out on today's gains.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Pharmaceutical Industries Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.